A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

In the span of eight months, Big Pharma companies took over four of the hottest radiopharmaceutical players in the industry.

The addition of camrelizumab to platinum-containing intensive neoadjuvant chemotherapy improved pathologic complete response ...

Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 ...

Mural nominated two new development candidates, MURA-8518 a novel binding protein-resistant IL-18 with half-life extension, ...

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he discusses opportunities for advancing the smart use of artificial ...

Each year, over 1.2 million Americans receive a cancer diagnosis, a journey that can be both overwhelming and daunting.

As I shift from an oncologist to a gynecologist for breast screenings, I examine both my reluctance to let go of the past and ...

New book exposes cancer diet myths, debunks misconceptions about fasting, sugar, and dairy, and advocates evidence-based nutrition to support patients through oncology treatment ...

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.